2022
Oncologic outcomes of neoadjuvant chemotherapy in patients with micropapillary variant urothelial carcinoma of the bladder
Rahman S, Lokeshwar S, Syed J, Javier-Desloges J, Press B, Choksi A, Rajwa P, Pradere B, Ploussard G, Kim J, Monaghan T, Renzulli J, Shariat S, Leapman M. Oncologic outcomes of neoadjuvant chemotherapy in patients with micropapillary variant urothelial carcinoma of the bladder. Urologic Oncology Seminars And Original Investigations 2022, 41: 107.e1-107.e8. PMID: 36481253, DOI: 10.1016/j.urolonc.2022.09.008.Peer-Reviewed Original ResearchConceptsVariant urothelial carcinomaNeoadjuvant chemotherapySubset of patientsUrothelial carcinomaOverall survivalPathologic responseRadical cystectomyNAC useClinical stage II diseaseHospital-based registry studyNeoadjuvant platinum-based chemotherapyPathologic lymph node positivityCox proportional hazards modelNational Cancer DatabaseStage II diseaseLymph node positivityPathologic complete responsePlatinum-based chemotherapyKaplan-Meier analysisMultivariable logistic regressionAnalysis of patientsBladder urothelial carcinomaProportional hazards modelCT2 diseasePathologic upstagingMP40-14 OVERALL SURVIVAL AMONG ELDERLY PATIENTS WITH LOCALIZED UPPER TRACT UROTHELIAL CARCINOMA RECEIVING OBSERVATION VERSUS DEFINITIVE TREATMENT
Rahman S, Syed J, Lokeshwar S, Press B, Monaghan T, Leapman M. MP40-14 OVERALL SURVIVAL AMONG ELDERLY PATIENTS WITH LOCALIZED UPPER TRACT UROTHELIAL CARCINOMA RECEIVING OBSERVATION VERSUS DEFINITIVE TREATMENT. Journal Of Urology 2022, 207: e680. DOI: 10.1097/ju.0000000000002600.14.Peer-Reviewed Original Research
2019
PD66-04 NATIONAL TRENDS AND PATHOLOGIC OUTCOMES OF NEOADJUVANT CHEMOTHERAPY AMONG PATIENTS WITH MICROPAPILLARY VARIANT UROTHELIAL CARCINOMA OF THE BLADDER
Javier-DesLoges* J, Abello A, Syed J, Sprenkle P, Hurwitz M, Kenney P, Leapman M. PD66-04 NATIONAL TRENDS AND PATHOLOGIC OUTCOMES OF NEOADJUVANT CHEMOTHERAPY AMONG PATIENTS WITH MICROPAPILLARY VARIANT UROTHELIAL CARCINOMA OF THE BLADDER. Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000557466.16539.88.Peer-Reviewed Original Research
2017
Impact of histologic subtype on bladder cancer outcome.
Washington S, Sanford T, Leapman M, Meng M, Porten S. Impact of histologic subtype on bladder cancer outcome. Journal Of Clinical Oncology 2017, 35: 391-391. DOI: 10.1200/jco.2017.35.6_suppl.391.Peer-Reviewed Original ResearchNational Cancer DatabaseVariant histologySmall cell carcinomaSquamous cell carcinomaBladder cancer outcomesCell carcinomaUrothelial carcinomaHazard ratioOverall survivalIndependent predictorsRadical cystectomyCancer outcomesBlack ethnicityBladder cancerMean age 67 yearsU.S. population-based cohortCommon variant histologyNon-urothelial histologyMultivariable Cox regressionSurgical margin statusAge 67 yearsPathologic T stageWorse overall survivalHistory of chemotherapyPopulation-based cohort